EED-IN-4

EED-IN-4 (compound 19) (40-80 mg/kg; p.o.; twice daily; from day 9 to day 30 post-immunization) dose-dependently alleviates clinical symptoms of the disease, reduces the degree of inflammatory infiltration in the spinal cord, and inhibits the activation and infiltration of dendritic cells, macrophages and pathogenic T cells in peripheral lymph nodes and the central nervous system in a female C57BL/6 mouse model of experimental autoimmune encephalomyelitis (EAE)^[1].
EED-IN-4 (100 mg/kg; p.o.; twice daily; for consecutive 30 days) shows no obvious acute or subacute toxicity in the C57BL/6 mouse model (with equal numbers of male and female mice). The mice exhibit normal body weight gain, no significant abnormalities in blood routine, liver and kidney function indices, and no histopathological damage in major organs including the heart, liver, spleen, lung and kidney^[1].
EED-IN-4 (80 mg/kg; intragastric administration (i.g.); single dose) preferentially and persistently accumulates in key immune lymph nodes including axillary, inguinal and cervical lymph nodes in healthy female C57BL/6 mice, with a concentration significantly higher than that of EED226, exhibiting favorable lymphoid tissue tropism^[1].